Baird Medical Charts 2025 Strategic Vision Following Milestone Year
Baird Medical Group (NASDAQ: BDMD) held its 2024 Annual Review and 2025 Planning Meeting at Baird Capital Tower in Guangzhou, China. The two-day event included participation in the 7th Thyroid Disease Forum and comprehensive reviews of market performance and future strategies.
Production Manager Le Zhang presented the 2025 production schedule and plans for enhanced after-sales service. The company's leadership discussed strengthening distributor relationships to support global expansion goals. The meeting highlighted Baird Medical's recent NASDAQ listing as a milestone that increased international recognition in the minimally invasive medical technologies sector.
Baird Medical Group (NASDAQ: BDMD) ha tenuto la sua Revisione Annuale 2024 e la Riunione di Pianificazione 2025 presso la Baird Capital Tower a Guangzhou, Cina. L'evento di due giorni ha incluso la partecipazione al 7° Forum sulle Malattie della Tiroide e revisioni complete delle performance di mercato e delle strategie future.
Il Responsabile di Produzione Le Zhang ha presentato il programma di produzione per il 2025 e i piani per un servizio post-vendita migliorato. I leader dell'azienda hanno discusso di come rafforzare le relazioni con i distributori per supportare gli obiettivi di espansione globale. La riunione ha messo in evidenza la recente quotazione di Baird Medical su NASDAQ come un traguardo che ha aumentato il riconoscimento internazionale nel settore delle tecnologie mediche minimamente invasive.
Baird Medical Group (NASDAQ: BDMD) llevó a cabo su Revisión Anual 2024 y Reunión de Planificación 2025 en la Baird Capital Tower en Guangzhou, China. El evento de dos días incluyó la participación en el 7° Foro de Enfermedades de la Tiroides y revisiones exhaustivas del rendimiento del mercado y estrategias futuras.
El Gerente de Producción Le Zhang presentó el cronograma de producción para 2025 y los planes para mejorar el servicio postventa. El liderazgo de la compañía discutió el fortalecimiento de las relaciones con los distribuidores para apoyar los objetivos de expansión global. La reunión destacó la reciente cotización de Baird Medical en NASDAQ como un hito que aumentó el reconocimiento internacional en el sector de tecnologías médicas mínimamente invasivas.
Baird Medical Group (NASDAQ: BDMD)는 중국 광저우의 Baird Capital Tower에서 2024년 연례 검토 및 2025년 계획 회의를 개최했습니다. 이틀간의 행사에는 제7회 갑상선 질환 포럼 참여와 시장 성과 및 향후 전략에 대한 포괄적인 검토가 포함되었습니다.
생산 관리자 Le Zhang은 2025년 생산 일정과 향상된 애프터 서비스 계획을 발표했습니다. 회사의 경영진은 글로벌 확장 목표를 지원하기 위해 유통업체 관계를 강화하는 방안에 대해 논의했습니다. 이번 회의는 Baird Medical의 최근 NASDAQ 상장 소식을 기념하며 최소 침습 의료 기술 분야에서의 국제적 인지도를 높인 성과로 강하게 부각되었습니다.
Baird Medical Group (NASDAQ: BDMD) a tenu sa Réunion Annuelle 2024 et sa Réunion de Planification 2025 au Baird Capital Tower à Guangzhou, en Chine. Cet événement de deux jours a inclus la participation au 7ème Forum sur les Maladies de la Thyroïde et des examens complets des performances du marché et des stratégies futures.
Le Responsable de Production Le Zhang a présenté le calendrier de production pour 2025 et les plans pour améliorer le service après-vente. La direction de l'entreprise a discuté du renforcement des relations avec les distributeurs pour soutenir les objectifs d'expansion mondiale. La réunion a mis en avant la récente cotation de Baird Medical sur NASDAQ comme un jalon ayant accru la reconnaissance internationale dans le secteur des technologies médicales peu invasives.
Baird Medical Group (NASDAQ: BDMD) fand seine jährliche Überprüfung 2024 und die Planungssitzung 2025 im Baird Capital Tower in Guangzhou, China, statt. Die zweitägige Veranstaltung umfasste die Teilnahme am 7. Forum für Schilddrüsenerkrankungen sowie umfassende Überprüfungen der Marktleistung und zukünftiger Strategien.
Produktionsleiter Le Zhang stellte den Produktionsplan für 2025 und Pläne zur Verbesserung des After-Sales-Services vor. Die Unternehmensführung diskutierte die Stärkung der Beziehungen zu Vertriebsunternehmen zur Unterstützung der globalen Expansionsziele. Die Sitzung hob die kürzliche NASDAQ-Notierung von Baird Medical hervor, die einen Meilenstein darstellt, der die internationale Anerkennung im Bereich der minimal invasiven Medizintechnologien erhöht hat.
- Successfully completed NASDAQ listing in 2024, enhancing international recognition
- None.
On the first day, company leaders participated in the 7th Thyroid Disease Forum in
On the second day, Production Manager Le Zhang shared updates on product development progress and the 2025 production schedule, including plans to enhance after-sales service. Executives and managers discussed strategies to strengthen distributor relationships, ensuring alignment with Baird Medical's global expansion goals.
In 2024, Baird Medical's NASDAQ listing expanded its international recognition, positioning the company for further success in minimally invasive medical technologies. As the company enters 2025, Baird Medical remains committed to advancing in this field, confident in the team's ability to drive innovation, achieve growth, and successfully execute its strategic vision for the year ahead.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-charts-2025-strategic-vision-following-milestone-year-302326993.html
SOURCE BDMD
FAQ
What key events did Baird Medical (BDMD) announce at its 2024 Annual Review meeting?
Where did Baird Medical (BDMD) hold its 2024 Annual Review meeting?
What significant milestone did Baird Medical (BDMD) achieve in 2024?
